A Study of BH-30236 in Relapsed/ Refractory Acute Myelogenous Leukemia and Higher Risk Myelodysplastic Syndrome

ClinicalTrials.gov ID: NCT06501196

Public ClinicalTrials.gov record NCT06501196. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced May 17, 2026, 10:43 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 1/1b Open-Label, Dose Escalation, First-in- Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Anti-leukemic Activity of the Orally Available CDC-Like Kinase (CLK) Inhibitor, BH-30236, in Adults With Relapsed or Refractory Acute Myelogenous Leukemia (R/R AML) or Higher-Risk Myelodysplastic Syndrome (HR-MDS)

Study identification

NCT ID: NCT06501196
Recruitment status: Recruiting
Study type: Interventional
Phase: Phase 1
Lead sponsor: BlossomHill Therapeutics; Industry
Enrollment: 170 participants

Conditions and interventions

Conditions

Interventions

BH-30236 Drug
Venetoclax Drug

Drug

Eligibility (public fields only)

Age range: 18 Years and older
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Jun 18, 2024
Primary completion: May 31, 2026
Completion: May 31, 2027
Last update posted: Sep 23, 2025

2024 – 2027

United States locations

U.S. sites: 13
U.S. states: 9
U.S. cities: 13

Facility	City	State	ZIP	Site status
City of Hope Medical Center	Duarte	California	91010	Recruiting
University of California Los Angeles	Los Angeles	California	90095	Recruiting
Stanford Cancer Center	Palo Alto	California	94304	Recruiting
Sylvester Comprehensive Cancer Center	Miami	Florida	33136	Recruiting
Moffitt Cancer Center	Tampa	Florida	33612	Recruiting
Northwestern Medicine - Northwestern Memorial Hospital Galter Pavilion	Chicago	Illinois	60611	Recruiting
Roswell Park Cancer Institute	Buffalo	New York	14263	Recruiting
Memorial Sloan Kettering Cancer Center	New York	New York	10065	Recruiting
The Ohio State University Wexner Medical Center - James Cancer Hosp	Columbus	Ohio	43210	Recruiting
Sarah Cannon Research Institute	Nashville	Tennessee	37203	Recruiting
The University of Texas M.D. Anderson Cancer Center	Houston	Texas	77030	Recruiting
Fred Hutchinson Cancer Center	Seattle	Washington	98109	Recruiting
University of Wisconsin Clinical Science Center	Madison	Wisconsin	53792	Recruiting

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT06501196, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Sep 23, 2025 · Synced May 17, 2026

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT06501196 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →